 |
|
|
| |
Switch from NNRTI plus FTC/TDF to Elvitegravir/C/F/TDF Maintains HIV Suppression and is Well-Tolerated
|
| |
| |
Reported by Jules Levin
21st Conference on Retroviruses and Opportunistic Infections
March 3-6, 2014
Boston, Massachusetts
A Pozniak,1 M Markowitz,2 A Mills,3 H Stellbrink,4 A Antela,5 P Domingo,6 P Girard,7 K Henry,8 W Garner,9 and B Guyer1Chelsea
and Westminster Hospital, London, UK; 2Aaron Diamond AIDS Research Center, NY, USA; 3Anthony Mills MD Inc., Los Angeles, CA, USA; 4ICH Study Center, Hamburg, Germany; 5Hospital Clinico Universitario, Santiago de Compostela, Spain; 6Hospital de la Santa Creu I Sant Pau, Barcelona, Spain; 7Hopital Saint-Antoine, Paris, France; 8Hennepin County Medical Center, Minneapolis, MN, USA; 9Gilead Sciences, Inc., Foster City, CA, USA
|
| |
|
|
|
|
|
